Acetic acid derivatives derivatives
Etodolac
Naphthyl acetic acid prodrug
Nabumetone
Cox-1 selective inhibitors
Acetylsalicylic acid ((Aspirin)at low dosage)
SalicylatesAcetylsalicylic acid (at high doses)
Amoxiprin
Benorylate/Benorilate
Choline magnesium salicylate
Ethenzamide
Faislamine
Methyl salicylate
Magnesium salicylate
Na. Salicylate
Na. thiosalicylate
Salicylic acid
Salicyl salicylate
Salicylamide
Difluorophenyl derivatives
Diflunisal
Indole acetic acids (Arylalkanoic acids)Aceclofenac
Acemethacin
Alclofenac
Bromfenac
Indomethacin
Oxametacin
Proglumetacin
Sulindac
Phenylacetic acid
Diclofenac potassium
Diclofenac sodium
Pyrolealkanoic acid
Tolmetin
2-Arylpropionic acids (profens)
Ibuprofen
Alminoprofen
Carprofen
Dexibuprofen
Dexketoprofen
Fenbufen
Fenoprofen
Flunoxaprofen
Flurbiprofen
Ibuproxam
Indoprofen
Ketoprofen (Actron, at least, has been withdrawn from the market.)
Ketorolac
Loxoprofen
Naproxen
Oxaprozin
Pirprofen
Suprofen
Tiaprofenic acid
N-Arylanthranilic acids (fenamic acids)Mefenamic acid
Flufenamic acid
Meclofenamate
Tolfenamic acid
Pyrazolidine derivatives
Phenylbutazone
Ampyrone
Apazone
Azapropazone
Clofezone
Kebuzone
Metamizole
Mofebutazone
Oxyphenbutazone
Phenazone
Sulfinpyrazone
OxicamsPiroxicam
Droxicam
Lornoxicam
Meloxicam
Tenoxicam
COX-2 inhibitorsCelecoxib (FDA has p-recautioned about its use)
OthersLicofelone
Omega-3 fatty acids
Licofelone acts by inhibiting LOX (lipooxygenase) & COX (cyclooxygenase)and hence known as
5-LOX/COX inhibitor.
Disease modifying anti-rheumatic agents (Slow acting anti-rheumatic agents):
Auranofin (Gold salts)
Aurothiomalate (Gold salts)
Chloroquine
Hydroxychloroquine
Leflunomide
Methotrexate
Penicillamine
Sulfasalazine
Anti-cytokines as anti-rheumatic agents:
Abatacept
Adalimumab
Anakinra
Etanercept
Infliximab
Rituximab
Further reading:
Safety and Efficacy of Non-Prescription (OTC) Analgesics and NSAIDs by K. D. Rainsford and M. C. Powanda
New NSAID appears effective for osteoarthritis: LOX-COX inhibitor.(Clinical Rounds)(licofelone): An article from: Family Practice News
by Mitchel L. Zoler
The Goodman and Gilman Manual of Pharmacology and Therapeutics by Laurence Brunton, Donald blumenthal, Iain buxton and Keith Parker
AHFS Drug Information 2008 (Ahfs Drug Information) by American Society of Health-system
Lippincott's Illustrated Reviews: Pharmacology, 4th Edition (Lippincott's Illustrated Reviews Series) by Richard A. Harvey, Pamela C. Champe, Richard Finkel, Luigi Cubeddu and Michelle A. Clarke
Copyright, (c), 2008, http://jeepakistan.blogspot.com
Tuesday, November 18, 2008
Tuesday, November 11, 2008
Novel and latest types of drugs and drug delivery systems
(WA Check) Newer drug delivery systems are more effective, target specific and more close to nature. Following are some of the novel drug delivery systems:
Products:
1. Radiopharmaceuticals
2. Biotechnology products:
a. Gene therapy
b. Hormones
c. Vaccines
d. Interleukins
e. Monoclonal antibodies
f. Peptides
g. Anti-sense drugs
h. Clotting factors
i. Erythropoietins
j. Colony stimulating factors
k. Tissue plasminogen activator
l. Tyrosine kinase inhibitor
m. Prostaglandins
3. Other techniques and products:
a. Nanocrystal particles
b. Nanogels (Jamie L. Gilmore et al.)
c. Block ionomer complexes (Jamie L. Gilmore et al.)
d. Nanotubes (Jamie L. Gilmore et al.)e. Nanofibers (Jamie L. Gilmore et al.)
f. Magnetic systems (WA Check)
g. Microspheres (Kelvin Hong et al.)
h. Temperature sensitive capsules (Sahraoui Chaieb et al.)
i. Dry powder injection (Terry L. Burkoth et al.)
Delivery systems:
1. Topical administration:
a. Iontophoresis
b. Phonophoresis
c. Controlled release microchips (John T. Santini, Jr., et al.)
2. Oral administration:
a. Mucoadhesive system
b. Osmotic pump
3. Vaginal Administration:
a. Intravaginal drug delivery system
b. Intrauterine progesterone drug delivery system
c. Dinoprostone vaginal insert
d. Estradiol vaginal ring
e. Bioadhesive vaginal gel
4.Ophthalmic products:
a. Inserts
5. Parenteral administration:
a. Liposomes
b. Niosomes
c. Long acting parenteral systems
6. Pegylated Dosage forms
7. Fusion protein
8. Implants
9. Autoinjection systems
References:
Jamie L. Gilmore, Xiang Yi, Lingdong Quan, and Alexander V. Kabanov. Novel Nanomaterials for Clinical Neuroscience. Journal of Neuroimmune Pharmacology. 2008 June; volume 3, Number 2, Pages 83–94.
John T. Santini, Jr.
Kelvin Hong, Afsheen Khwaja, Eleni Liapi, Michael S. Torbenson, Cristos S. Georgiades and Jean-Francois H. Geschwind. New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver Cancer. Clinical Cancer Research Volume 12, Pages 2563-2567.
Sahraoui Chaieb
Terry L. Burkoth, Drug delivery by transdermal and transmucosal powder injection
WA Check. New drugs and drug-delivery systems in the year 2000. American Journal of Hospital Pharmacy, Vol 41, Issue 8, Pages 1536-1547.
Further Reading:
Targeted & Controlled Drug Delivery: Novel Carrier Systems by Vyas / Khar
Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development (Drugs and the Pharmaceutical Sciences) by Edith Mathiowitz, Donald E. Chickering III and Claus-Michael Lehr
Progress in Controlled and Novel Drug Delivery Systems by N. K. Jain
Nanoparticulate Drug Delivery Systems (Drugs and the Pharmaceutical Sciences) by Deepak Thassu, Michel Deleers and Yashwant Pathak
Gene therapy: Gene Therapy: Treating Disease by Repairing Genes (New Biology) by Joseph Ph.D. Panno
Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Third Edition by Nancy Smyth Templeton
Interleukins: Interleukin Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) by Luke A. J. Neil and Andrew Bowie
Therapeutic Applications of Interleukin-2 (Basic and Clinical Oncology) by Michael Atkins
Monoclonal Antibodies: Handbook of Therapeutic Monoclonal Antibodies by an Zhiqiang and william strohl
Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology) by Maher albitar
Colony stimulating factors: Colony-stimulating Factors by John M. Garland
Fusion Proteins: Antibody Fusion Proteins by Steven M. Chamow and Avi Achkenazi
Copyright, (c), 2008, http://jeepakistan.blogspot.com
Products:
1. Radiopharmaceuticals
2. Biotechnology products:
a. Gene therapy
b. Hormones
c. Vaccines
d. Interleukins
e. Monoclonal antibodies
f. Peptides
g. Anti-sense drugs
h. Clotting factors
i. Erythropoietins
j. Colony stimulating factors
k. Tissue plasminogen activator
l. Tyrosine kinase inhibitor
m. Prostaglandins
3. Other techniques and products:
a. Nanocrystal particles
b. Nanogels (Jamie L. Gilmore et al.)
c. Block ionomer complexes (Jamie L. Gilmore et al.)
d. Nanotubes (Jamie L. Gilmore et al.)e. Nanofibers (Jamie L. Gilmore et al.)
f. Magnetic systems (WA Check)
g. Microspheres (Kelvin Hong et al.)
h. Temperature sensitive capsules (Sahraoui Chaieb et al.)
i. Dry powder injection (Terry L. Burkoth et al.)
Delivery systems:
1. Topical administration:
a. Iontophoresis
b. Phonophoresis
c. Controlled release microchips (John T. Santini, Jr., et al.)
2. Oral administration:
a. Mucoadhesive system
b. Osmotic pump
3. Vaginal Administration:
a. Intravaginal drug delivery system
b. Intrauterine progesterone drug delivery system
c. Dinoprostone vaginal insert
d. Estradiol vaginal ring
e. Bioadhesive vaginal gel
4.Ophthalmic products:
a. Inserts
5. Parenteral administration:
a. Liposomes
b. Niosomes
c. Long acting parenteral systems
6. Pegylated Dosage forms
7. Fusion protein
8. Implants
9. Autoinjection systems
References:
Jamie L. Gilmore, Xiang Yi, Lingdong Quan, and Alexander V. Kabanov. Novel Nanomaterials for Clinical Neuroscience. Journal of Neuroimmune Pharmacology. 2008 June; volume 3, Number 2, Pages 83–94.
John T. Santini, Jr.
Kelvin Hong, Afsheen Khwaja, Eleni Liapi, Michael S. Torbenson, Cristos S. Georgiades and Jean-Francois H. Geschwind. New Intra-arterial Drug Delivery System for the Treatment of Liver Cancer: Preclinical Assessment in a Rabbit Model of Liver Cancer. Clinical Cancer Research Volume 12, Pages 2563-2567.
Sahraoui Chaieb
Terry L. Burkoth, Drug delivery by transdermal and transmucosal powder injection
WA Check. New drugs and drug-delivery systems in the year 2000. American Journal of Hospital Pharmacy, Vol 41, Issue 8, Pages 1536-1547.
Further Reading:
Targeted & Controlled Drug Delivery: Novel Carrier Systems by Vyas / Khar
Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development (Drugs and the Pharmaceutical Sciences) by Edith Mathiowitz, Donald E. Chickering III and Claus-Michael Lehr
Progress in Controlled and Novel Drug Delivery Systems by N. K. Jain
Nanoparticulate Drug Delivery Systems (Drugs and the Pharmaceutical Sciences) by Deepak Thassu, Michel Deleers and Yashwant Pathak
Gene therapy: Gene Therapy: Treating Disease by Repairing Genes (New Biology) by Joseph Ph.D. Panno
Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Third Edition by Nancy Smyth Templeton
Interleukins: Interleukin Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) by Luke A. J. Neil and Andrew Bowie
Therapeutic Applications of Interleukin-2 (Basic and Clinical Oncology) by Michael Atkins
Monoclonal Antibodies: Handbook of Therapeutic Monoclonal Antibodies by an Zhiqiang and william strohl
Monoclonal Antibodies: Methods and Protocols (Methods in Molecular Biology) by Maher albitar
Colony stimulating factors: Colony-stimulating Factors by John M. Garland
Fusion Proteins: Antibody Fusion Proteins by Steven M. Chamow and Avi Achkenazi
Copyright, (c), 2008, http://jeepakistan.blogspot.com
Friday, October 31, 2008
Classification of sulfonamides
Detailed classification of Sulfonamides
List of Antibiotic Sulfonamides on the basis of concentration-time data:1. Short Acting Sulfonamide:
a. Sulfadiazine
b. Sulfadimidine
c. Sulfamethizole
d. Sulfamethoxazole
e. Sulfisoxazole
f. Sulfisomidine or sulfaisodimidine
g. Sulfathiazole (Veterinary Product)
h. Trisulfapyrimidine (Veterinary Product)
2. Intermediate Acting Sulfonamide:
a. Sulacetamide
b. Sulfadoxine
c. Sulfamimethoxine (Veterinary Product)
d. Sulfamethoxazole (Veterinary Product)
e. Sulfamethazine (Veterinary Product)
f. Sulfadiazine (Veterinary Product)
3. Long Acting Sulfonamide:
a. Sulfadoxine
b. Sulfamethoxy-pyridazine
c. Sulfametopyrazine
d. Sulfaphenazole
e. Sulfadimethoxine (Veterinary Product)
List of Diuretic Sulfonamides:
a. Acetazolamide
b. Benzolamide
c. Bumetanide
d. Ethoxzolamide
e. Methazolamide
f. Dichlorophenamide or Diclophenamide
g. Chlorthalidone
h. Clopamide
i. Dorzolamide
j. Furosemide
k. Hydrochlorothiazide
l. Indapamide
m. Mefruside
n. Metolazone
o. Xipamide
List of Sulfonamides for local application:
a. Mafenide
b. Silver sulfadiazine
c. Sulacetamide
d. Sulfapyridine
List of Sulfonamides for GIT disturbance:
a. Phthalyl sulfathiazole
b. Sulfasalazine
Further Reading:
The Goodman and Gilman Manual of Pharmacology and Therapeutics by Laurence Brunton, Donald blumenthal, Iain buxton and Keith Parker
AHFS Drug Information 2008 (Ahfs Drug Information) by American Society of Health-system
Lippincott's Illustrated Reviews: Pharmacology, 4th Edition (Lippincott's Illustrated Reviews Series) by Richard A. Harvey, Pamela C. Champe, Richard Finkel, Luigi Cubeddu and Michelle A. Clarke
Food Safety; Contaminants and Toxins, edited by J. P. F. D'Mello
Copyright, (c), 2011, http://jeepakistan.blogspot.com
Monday, October 27, 2008
Atropine
Atropine is a naturally occuring anti-muscarinic agent.
Copyrights, (c), 2008, http://jeepakistan.blogspot.com
Copyrights, (c), 2008, http://jeepakistan.blogspot.com
Wednesday, October 15, 2008
Classification of cephalosporins
These are chemically and in their mode of action similar to penicillin.
These are classified according to the generations:
First generation cephalosporins:
a. Cefacetrile,
b. Cefadroxil (R. E. Buck et al.) (Oral),
c. Cefalexin, (Oral)
d. Cefaloglycin,
e. Cefalonium,
f. Cefaloridine, (Parenteral)
g. Cefalothin, (Parenteral)
h. Cefapirin, (Parenteral)
i. Cefatrizine,
j. Cefazedone,
k. Cefazaflur,
l. Cefazolin, (Parenteral)
m. Cefradine, (Oral)
n. Cefroxadine,
o. Ceftezole
Second generation cephalosporins:
a. Cefaclor, (Oral)
b. Cefamandole, (Parenteral)
c. Cefmetazole, (Parenteral)
d. Cefminox,
e. Cefonicid, (Parenteral)
f. Ceforanide, (Parenteral)
g. Cefoxitin, (Parenteral)
h. Cefotiam,
i. Cefotetan, (Parenteral)
j. Cefprozil, (Parenteral)
k. Cefbuperazone,
l. Cefuroxime, (Parenteral)
m. Cefuzonam,
n. Loracarbef (Parenteral)
Third generation cephalosporins:
a. Cefcapene,
b. Cefdaloxime,
c. Cefdinir,
d. Cefditoren,
e. Cefetamet,
f. Cefixime, (Parenteral)
g. Cefmenoxime,
h. Cefodizime,
i. Cefoperazone, (Parenteral)
j. Cefotaxime, (Parenteral)
k. Cefpimizole,
l. Cefpiramide,
m. Cefpodoxime,
n. Cefsulodin,
o. Ceftazidime, (Parenteral)
p. Cefteram,
q. Ceftibuten,
r. Ceftiolene,
s. Ceftizoxime, (Parenteral)
t. Ceftriaxone, (Parenteral)
u. Flomoxef,
v. Latamoxef,
w. Moxalactam (Parenteral)
Fourth generation cephalosporins:
a. Cefepime,
b. Cefozopran,
c. Cefpirome,
d. Cefquinome
Fifth generation cephalosporins:
a. Ceftobiprole (Tatiana Bogdanovich et al.) (Andreas F. Widmer)
b. Ceftaroline (S Crofskey)
References:
Andreas F. Widmer, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland. http://www.sld.cu/galerias/pdf/sitios/apua-cuba/v4-ceftobiprole._a_new_option_for_treatment_of_skin_and_soft-tissue_infections.pdf
R. E. Buck, K. E. Price. Cefadroxil, a new broad-spectrum cephalosporin. Infection (Journal), Volume 8, Supplement - 5, September, 1980, Pages S532-S537.
S. Crofskey. Ceftaroline a strong competitor in cSSSI. Inpharma weekly, October 14, 2006, Issue 1559, 7-8.
Tatiana Bogdanovich, Lois M. Ednie, Stuart Shapiro, Peter C. Appelbaum. Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin. Antimicrobial agents and chemotherapy, October 2005, Volume 49, Number 10, Pages 4210-4219.
Further Reading:
The Goodman and Gilman Manual of Pharmacology and Therapeutics by Laurence Brunton, Donald blumenthal, Iain buxton and Keith Parker
AHFS Drug Information 2008 (Ahfs Drug Information) by American Society of Health-system
Lippincott's Illustrated Reviews: Pharmacology, 4th Edition (Lippincott's Illustrated Reviews Series) by Richard A. Harvey, Pamela C. Champe, Richard Finkel, Luigi Cubeddu and Michelle A. Clarke
Copyright (c), 2008, http://jeepakistan.blogspot.com
All rights reserved.
These are classified according to the generations:
First generation cephalosporins:
a. Cefacetrile,
b. Cefadroxil (R. E. Buck et al.) (Oral),
c. Cefalexin, (Oral)
d. Cefaloglycin,
e. Cefalonium,
f. Cefaloridine, (Parenteral)
g. Cefalothin, (Parenteral)
h. Cefapirin, (Parenteral)
i. Cefatrizine,
j. Cefazedone,
k. Cefazaflur,
l. Cefazolin, (Parenteral)
m. Cefradine, (Oral)
n. Cefroxadine,
o. Ceftezole
Second generation cephalosporins:
a. Cefaclor, (Oral)
b. Cefamandole, (Parenteral)
c. Cefmetazole, (Parenteral)
d. Cefminox,
e. Cefonicid, (Parenteral)
f. Ceforanide, (Parenteral)
g. Cefoxitin, (Parenteral)
h. Cefotiam,
i. Cefotetan, (Parenteral)
j. Cefprozil, (Parenteral)
k. Cefbuperazone,
l. Cefuroxime, (Parenteral)
m. Cefuzonam,
n. Loracarbef (Parenteral)
Third generation cephalosporins:
a. Cefcapene,
b. Cefdaloxime,
c. Cefdinir,
d. Cefditoren,
e. Cefetamet,
f. Cefixime, (Parenteral)
g. Cefmenoxime,
h. Cefodizime,
i. Cefoperazone, (Parenteral)
j. Cefotaxime, (Parenteral)
k. Cefpimizole,
l. Cefpiramide,
m. Cefpodoxime,
n. Cefsulodin,
o. Ceftazidime, (Parenteral)
p. Cefteram,
q. Ceftibuten,
r. Ceftiolene,
s. Ceftizoxime, (Parenteral)
t. Ceftriaxone, (Parenteral)
u. Flomoxef,
v. Latamoxef,
w. Moxalactam (Parenteral)
Fourth generation cephalosporins:
a. Cefepime,
b. Cefozopran,
c. Cefpirome,
d. Cefquinome
Fifth generation cephalosporins:
a. Ceftobiprole (Tatiana Bogdanovich et al.) (Andreas F. Widmer)
b. Ceftaroline (S Crofskey)
References:
Andreas F. Widmer, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland. http://www.sld.cu/galerias/pdf/sitios/apua-cuba/v4-ceftobiprole._a_new_option_for_treatment_of_skin_and_soft-tissue_infections.pdf
R. E. Buck, K. E. Price. Cefadroxil, a new broad-spectrum cephalosporin. Infection (Journal), Volume 8, Supplement - 5, September, 1980, Pages S532-S537.
S. Crofskey. Ceftaroline a strong competitor in cSSSI. Inpharma weekly, October 14, 2006, Issue 1559, 7-8.
Tatiana Bogdanovich, Lois M. Ednie, Stuart Shapiro, Peter C. Appelbaum. Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin. Antimicrobial agents and chemotherapy, October 2005, Volume 49, Number 10, Pages 4210-4219.
Further Reading:
The Goodman and Gilman Manual of Pharmacology and Therapeutics by Laurence Brunton, Donald blumenthal, Iain buxton and Keith Parker
AHFS Drug Information 2008 (Ahfs Drug Information) by American Society of Health-system
Lippincott's Illustrated Reviews: Pharmacology, 4th Edition (Lippincott's Illustrated Reviews Series) by Richard A. Harvey, Pamela C. Champe, Richard Finkel, Luigi Cubeddu and Michelle A. Clarke
Copyright (c), 2008, http://jeepakistan.blogspot.com
All rights reserved.
Subscribe to:
Posts (Atom)
-
Q: What do you know about ergot alkaloids? Ans: These include alkaloids which we get from the ergot fungus Claviceps purpurea or derived ...
-
(For detailed study of Pharmaceutical Incompatibility Click here) Multiple Choice Questions (MCQs) from Pharmaceutical Incompatibility in ...
-
Multiple Choice Questions (MCQs) of Powders and Granules from Pharmaceutics 1. _______ powders consist of more than one ingredients. a. Si...